Is intra-arterial application of targeted radionuclide therapy in neuro-oncology worth the effort? A framework for evidence generation
The Lancet Medical Imaging & Theranostics · 2026-11 · 100041
DOI: 10.1016/j.lanmit.2026.100041 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026-11. Verfasst von Jonas Reis und 8 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Targeted radionuclide therapy is an established practice in extracranial oncology; however, translating this therapy to CNS tumours is challenged by delivery barriers, heterogeneous target expression, and low intratumoural activity after intravenous administration. Intra-arterial delivery via superselective catheterisation of tumour-feeding arteries has been proposed to raise first-pass intratumoural exposure and absorbed dose. Meningiomas, owing to their frequent SSTR2 expression, accessible dural arterial supply, and an extra-axial location allowing the route effect to be assessed without barrier confounding, are the most suitable setting for initial evaluation of intra-arterial delivery. Although early intra-arterial case series showed feasibility and increased uptake, controlled intra-arterial versus intravenous comparisons and standardised post-therapy dosimetry are absent. For gliomas and brain metastases, evidence on intra-arterial delivery is restricted to small-scale early-phase imaging studies. Whether intra-arterial application is worth the effort depends on showing reproducible absorbed-dose gain corresponding with improved clinical outcomes. In this Review, we propose a staged development pathway structured around four decision gates, anchored by an intrapatient dosimetric comparison of intra-arterial versus intravenous delivery to establish whether intra-arterial administration provides an absorbed-dose advantage sufficient to warrant subsequent efficacy evaluation.
Zitieren
APA
Reis, J., Braat, A. J. A. T., Tolboom, N., Vindstad, B. E., Schaaf, I. C. V. D., Zanten, S. V. V., Deroose, C. M., Preusser, M., & Albert, N. L. (2026). Is intra-arterial application of targeted radionuclide therapy in neuro-oncology worth the effort? A framework for evidence generation. The Lancet Medical Imaging & Theranostics, 100041. https://doi.org/10.1016/j.lanmit.2026.100041
Vancouver
Reis J, Braat AJAT, Tolboom N, Vindstad BE, Schaaf ICVD, Zanten SVV, et al. Is intra-arterial application of targeted radionuclide therapy in neuro-oncology worth the effort? A framework for evidence generation. The Lancet Medical Imaging & Theranostics. 2026:100041. doi:10.1016/j.lanmit.2026.100041
BibTeX
@article{Reis2026,
author = {Reis, Jonas and Braat, Arthur J A T and Tolboom, Nelleke and Vindstad, Benedikte Emilie and Schaaf, Irene C van der and Zanten, Sophie Veldhuijzen van and Deroose, Christophe M and Preusser, Matthias and Albert, Nathalie L},
title = {Is intra-arterial application of targeted radionuclide therapy in neuro-oncology worth the effort? A framework for evidence generation},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
pages = {100041},
doi = {10.1016/j.lanmit.2026.100041}
}
EUVIMED